Literature DB >> 23901015

Cutaneous herpes zoster.

Sharmila Sengupta1.   

Abstract

Cutaneous herpes zoster is a benign, localized painful skin lesion, more common in the elderly and immunocompromised population across the globe. It is caused by reactivation of the varicella zoster virus lying dormant in the dorsal root ganglion. Although self-limiting in nature, it can cause protean complications in the vulnerable patient. The advent of antiviral therapy and an FDA-approved vaccine has reduced the morbidity of the disease considerably. However, focused research on the disease-modulating factors and prevention in the immunocompromised are still issues that warrant research. The current understanding of cutaneous herpes zoster and its pathogenesis, complications, and management are discussed in this review.

Entities:  

Year:  2013        PMID: 23901015     DOI: 10.1007/s11908-013-0356-y

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.663


  63 in total

Review 1.  Managing ophthalmic herpes zoster in primary care.

Authors:  Wim Opstelten; Michel J W Zaal
Journal:  BMJ       Date:  2005-07-16

2.  Q: Who should receive the shingles vaccine?

Authors:  Aparajita Singh; Kristin Englund
Journal:  Cleve Clin J Med       Date:  2009-01       Impact factor: 2.321

Review 3.  The relation between systematic reviews and practice guidelines.

Authors:  D J Cook; N L Greengold; A G Ellrodt; S R Weingarten
Journal:  Ann Intern Med       Date:  1997-08-01       Impact factor: 25.391

4.  Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study.

Authors:  Ya-Wen Yang; Yi-Hua Chen; Kuo-Hsien Wang; Chen-Yi Wang; Hui-Wen Lin
Journal:  CMAJ       Date:  2011-02-22       Impact factor: 8.262

5.  Age related seroprevalence of antibodies to varicella in India.

Authors:  M R Lokeshwar; A Agrawal; S D Subbarao; M S Chakraborty; A V Ram Prasad; J Weil; H L Bock; S Kanwal; R C Shah; N Shah
Journal:  Indian Pediatr       Date:  2000-07       Impact factor: 1.411

6.  A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients.

Authors:  S Tyring; R Belanger; W Bezwoda; P Ljungman; R Boon; R L Saltzman
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

7.  Immunological findings in cigarette smokers.

Authors:  P Moszczyński; Z Zabiński; P Moszczyński; J Rutowski; S Słowiński; Z Tabarowski
Journal:  Toxicol Lett       Date:  2001-01-03       Impact factor: 4.372

8.  Herpes zoster in patients with treated Wegener's granulomatosis. A possible role for cyclophosphamide.

Authors:  T R Cupps; G J Silverman; A S Fauci
Journal:  Am J Med       Date:  1980-12       Impact factor: 4.965

Review 9.  Review of varicella zoster seroepidemiology in India and Southeast Asia.

Authors:  B W Lee
Journal:  Trop Med Int Health       Date:  1998-11       Impact factor: 2.622

10.  Family history as a risk factor for herpes zoster: a case-control study.

Authors:  Lindsey D Hicks; Robert H Cook-Norris; Natalia Mendoza; Vandana Madkan; Anita Arora; Stephen K Tyring
Journal:  Arch Dermatol       Date:  2008-05
View more
  2 in total

Review 1.  Herpes Zoster in the Older Adult.

Authors:  Amrita R John; David H Canaday
Journal:  Infect Dis Clin North Am       Date:  2017-12       Impact factor: 5.982

2.  Varicella-zoster meningitis in an immunocompetent young man presenting with a painless erythematous rash.

Authors:  Sahand Imani; Natalie C Palavra; Carly Oboudiyat; Jerome Ip
Journal:  BMJ Case Rep       Date:  2020-01-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.